Analysis of MET mRNA expression in gastric cancers using RNA in situ hybridization assay: Its clinical implication and comparison with immunohistochemistry and silver in situ hybridization

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Choi, Jiwoon ^a   Lee, Hee Eun ^a   Kim, Min A ^a   Jang, Bo Gun ^a   Lee, Hye Seung ^b   Kim, Woo Ho ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MET GENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RNA IN SITU HYBRIDIZATION; SILVER IN SITU HYBRIDIZATION; STOMACH CANCER; TUMOR INVASION; CANCER GRADING; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR BURDEN; YOUNG ADULT;

EID: 84909592369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111658     Document Type: Article

References (28)

1. Peters S, Adjei AA (2012) MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9: 314-326.
2. Dean M, Park M, Le Beau MM, Robins TS, Diaz MO, et al. (1985) The human met oncogene is related to the tyrosine kinase oncogenes. Nature 318: 385-388.
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, et al. (1991) Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 251: 802-804.
4. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103.
5. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, et al. (1992) Karyotypic analysis of gastric carcinoma cell lines carrying an amplified cmet oncogene. Cancer Genet Cytogenet 64: 170-173.
6. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189: 227-232.
7. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, et al. (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902.
8. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS (2001) Overexpression of the cmet protooncogene in human gastric carcinoma-correlation to clinical features. Acta Oncol 40: 638-643.
9. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, et al. (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19: 1477-1483.
10. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29: 4789-4795.
11. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, et al. (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25: 1517-1524.
12. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, et al. (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29: 4803-4810.
13. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, et al. (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107: 325-333.
14. Ha SY, Lee J, Kang SY, Do IG, Ahn S, et al. (2013) MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 26: 1632-1641.
15. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, et al. (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103: 2316-2321.
16. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, et al. (2011) Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 1: 573-579.
17. Kaji M, Yonemura Y, Harada S, Liu X, Terada I, et al. (1996) Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. Cancer Gene Ther 3: 393-404.
18. Hara T, Ooi A, Kobayashi M, Mai M, Yanagihara K, et al. (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78: 1143-1153.
19. Wang F, Flanagan J, Su N, Wang LC, Bui S, et al. (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14: 22-29.
20. Kim MA, Jung JE, Lee HE, Yang HK, Kim WH (2013) In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. Hum Pathol 44: 487-494.
21. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643-655.
22. Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y, Tahara E (1993) Aberrant expression of c-met mRNA in human gastric carcinomas. Int J Cancer 55: 72-75.
23. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, et al. (2012) Coexpression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 130: 2912-2921.
24. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, et al. (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296.
25. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, et al. (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027.
26. Park WS, Oh RR, Kim YS, Park JY, Shin MS, et al. (2000) Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. Apmis 108: 195-200.
27. Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, et al. (2010) Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem Biophys Res Commun 394: 1042-1046.
28. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, et al. (2000) Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19: 1547-1555.